PRISM Study-Pruritus Relief Through Itch Scratch Modulation

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

August 7, 2018

Primary Completion Date

May 10, 2022

Study Completion Date

February 24, 2023

Conditions
Prurigo Nodularis
Interventions
DRUG

Nalbuphine ER Tablets

Active Nalbuphine ER Tablets

DRUG

Placebo Tablets

Placebo matching NAL ER with no active substance

Trial Locations (70)

4020

Study Site 402, Linz

8036

Study Site 401, Graz

10117

Study Site 216, Berlin

10247

Study Site 209, Berlin

10789

Study Site 208, Berlin

11794

Study Site 134, Stony Brook

17033

Study Site 132, Hershey

19103

Study Site 106, Philadelphia

20037

Study Site 128, Washington D.C.

20246

Study Site 215, Hamburg

20850

Study Site 102, Rockville

22391

Study Site 222, Hamburg

24105

Study Site 214, Kiel

26505

Study Site 148, Morgantown

28411

Study Site 101, Wilmington

29407

Study Site 147, Charleston

29609

Study Site 501, Brest

32819

Study Site 158, Orlando

33143

Study Site 108, South Miami

33433

Study Site 138, Boca Raton

33615

Study Site 142, Tampa

35055

Study Site 303, Rzeszów

37421

Study Site 140, Chattanooga

37917

Study Site 145, Knoxville

40225

Study Site 221, Düsseldorf

44106

Study Site 120, Cleveland

45219

Study Site 122, Cincinnati

48084

Study Site 139, Troy

48103

Study Site 143, Ann Arbor

48149

Study Site 202, Münster

48455

Study Site 205, Bad Bentheim

50566

Study Site 302, Wroclaw

50937

Study Site 219, Cologne

55131

Study Site 201, Mainz

60590

Study Site 204, Frankfurt am Main

64506

Study Site 118, Saint Joseph

69115

Study Site 212, Heidelberg

70178

Study Site 206, Stuttgart

75010

Study Site 502, Paris

77598

Study Site 103, Webster

78705

Study Site 137, Austin

80802

Study Site 220, München

84088

Study Site 150, West Jordan

85006

Study Site 151, Phoenix

89052

Study Site 144, Henderson

89119

Study Site 146, Las Vegas

91606

Study Site 141, North Hollywood

92677

Study Site 157, Laguna Niguel

94115

Study Site 130, San Francisco

94538

Study Site 121, Fremont

99202

Study Site 135, Spokane

02114

Study Site 136, Boston

02135

Study Site 153, Brighton

03801

Study Site 109, Portsmouth

07601

Study Site 159, Hackensack

02919

Study Site 131, Johnston

29425-8908

Study Site 107, Charleston

01307

Study Site 213, Dresden

15-453

Study Site 304, Bialystok

40-648

Study Site 306, Katowice

31-302

Study Site 308, Krakow

31-559

Study Site 316, Krakow

90-265

Study Site 309, Lodz

20-406

Study Site 314, Lublin

27-400

Study Site 305, Ostrowiec Świętokrzyski

60-529

Study Site 313, Poznan

60-848

Study Site 315, Poznan

01-142

Study Site 310, Warsaw

01-817

Study Site 301, Warsaw

02-962

Study Site 312, Warsaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Trevi Therapeutics

INDUSTRY

NCT03497975 - PRISM Study-Pruritus Relief Through Itch Scratch Modulation | Biotech Hunter | Biotech Hunter